Current Perspectives on the US FDA Regulatory Framework for Intelligent drug-delivery Systems

• US FDA. Considering whether an FDA-regulated product involves the application of nanotechnology. Guidance for industry (draft) (2011).
   Google Scholar
• Hamburg MA . FDA‘s approach to regulation of products of nanotechnology. Science366, 299–300 (2012).
   Google Scholar
• Garg S , SerruysPW. Coronary stents: looking forward. J. Am. Coll. Cardiol.56(10), S43–S78 (2010).
   PubMed Web of Science ®Google Scholar
• Douglas SM , BacheletI, ChurchGM. A logic-gated nanorobot for targeted transport of molecular payloads. Science335(6070), 831–834 (2012).
   PubMed Web of Science ®Google Scholar
• Chen L , HeneinG, LucianiV. Nanofabrication techniques for controlled drug-release devices. Nanomed.6(1), 1–6 (2011).
   PubMed Web of Science ®Google Scholar
• Farra R , SheppardNF, McCabeLet al. First in human testing of a wirelessly controlled drug delivery microchip. Sci. Tansl. Med. 4(122), 122ra21 (2012).
   PubMed Web of Science ®Google Scholar
• Pirmoradi FN , JacksonJK, BurtHM, ChiaoM. A magnetically controlled MEMS device for drug delivery: design, fabrication, and testing. Lab. Chip11(18), 3072–3080 (2011).
   PubMed Web of Science ®Google Scholar
• Staples M . Microchips and controlled-release drug reservoirs. Wiley Interdiscip Rev Nanomed Nanobiotechnol.2(4), 400–417 (2010).
   PubMed Web of Science ®Google Scholar
• Zhou M , ZhouN, KuralayFet al. A self-powered ‘sense-act-treat‘ system that is based on a biofuel cell and controlled by boolean logic. Angew. Chem. Int. Ed. 51(11), 2686–2689 (2012).
   PubMed Web of Science ®Google Scholar
• Alvarez-Lorenzo C , BrombergL, ConcheiroA. Light-sensitive drug delivery systems. Photochem. Photobiol.85(4), 848–860 (2009).
   PubMed Web of Science ®Google Scholar
• Pirmoradi FN , ChengL, ChiaoM. A magnetic poly(dimethylesiloxane)composite membrane incorporated with uniformly dispersed, coated iron oxide nanoparticles. J. Micromech. Microeng.20(1), 015032 (2010).
   Google Scholar
• Milane L , GaneshS, ShahS, DuanZ, AmijiM. Multi-modal strategies for overcoming tumor drug resistance: hypoxia, the Warburg effect, stem cells and multifunctional nanotechnology. J. Control. Release155(2), 237–247 (2011).
   PubMed Web of Science ®Google Scholar
• Reddy LH , CouvreurP. Nanotechnology for therapy and imaging of liver diseases. J. Hepatol.55(6), 1461–1466 (2011).
   PubMed Web of Science ®Google Scholar
• US FDA. Content and format of investigation new drug applications for Phase 1 studies of drugs, including well-characterized, therapeutic, biotechnology-derived products (1995).
   Google Scholar
• US FDA. Center for Drug Evaluation and Research. CGMP for Phase 1 Investigational Drugs (2008).
   Google Scholar
• Torchilin V . Antibody-modified liposomes for cancer chemotherapy. Expert Opin. Drug. Deliv.5(9), 1003–1025 (2008).
   PubMed Web of Science ®Google Scholar
• US FDA. Liposome drug products; chemistry, manufacturing, and controls; human pharmacokinetics and bioavailability; and labeling documentation (2002).
   Google Scholar
• Reichert JM , Valge-ArcherVE. Development trends for monoclonal antibody cancer therapeutics. Nat. Rev. Drug Discov.6, 349–356 (2007).
   PubMed Web of Science ®Google Scholar
• US FDA. Points to consider in the manufacture and testing of monoclonal antibody products for human use (1997).
   Google Scholar
• Petrelli F , BorgonovaK, BarniS. Targeted delivery for breast cancer therapy: the history of nano-article-albumin-bound paclitaxel. Expert. Opin. Pharmacother.11(8), 1413–1432 (2010).
   PubMed Web of Science ®Google Scholar
• Sapsford KE , TezakZ, KondratovichM, PacanowskiMA, ZinehI, MansfieldE. Biomarkers to improve the benefit/risk balance for approved therapeutics: a US FDA perspective on personalized medicine. Therapeut. Del.1(5), 631–641 (2010).
   PubMedGoogle Scholar
• Lauritsen KJ , NguyenT. Combination products regulation at the FDA.85(5), 468–470 (2009).
   Google Scholar

Websites

• Federal food, drug and cosmetic act section 201(h), 21 U.S.C. 321(h). www.fda.gov/RegulatoryInformation/Legislation/FederalFoodDrugandCosmeticActFDCAct/default.htm
   Google Scholar
• Overview of device regulation: introduction. www.fda.gov/MedicalDevices/DeviceRegulationandGuidance/Overview/default.htm
   Google Scholar
• Federal food, drug and cosmetic act section 513; 21 U.S.C. §360c. www.fda.gov/RegulatoryInformation/Legislation/FederalFoodDrugandCosmeticActFDCAct/default.htm
   Google Scholar
• Code of federal regulations Title 21. www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfcfr/cfrsearch.cfm
   Google Scholar
• Draft guidance for industry and US FDA staff: medical device classification product codes. www.fda.gov/MedicalDevices/DeviceRegulationandGuidance/GuidanceDocuments/ucm85317.htm
   Google Scholar
• Guidance for industry and US FDA staff: factors to consider when making benefit-risk determinations in medical device premarket approval and de novo classifications. www.fda.gov/downloads/MedicalDevices/DeviceRegulationandGuidance/GuidanceDocuments/UCM296379.pdf
   Google Scholar
• General and special controls. www.fda.gov/MedicalDevices/DeviceRegulationandGuidance/Overview/GeneralandSpecialControls/default.htm
   Google Scholar
• Draft guidance for industry and US FDA staff: the 510(k) program: evaluating substantial equivalence in premarket notifications. www.fda.gov/MedicalDevices/DeviceRegulationandGuidance/GuidanceDocuments/ucm282958.htm
   Google Scholar
• New section 513(f)(2) – evaluation of automatic class III designation, guidance for industry and CDRH staff. www.fda.gov/MedicalDevices/DeviceRegulationandGuidance/GuidanceDocuments/ucm080195.htm
   Google Scholar
• S. 3187: Food and Drug Administration Safety and Innovation Act www.govtrack.us/congress/bills/112/s3187
   Google Scholar
• Guidance documents (medical devices and radiation emitting products). www.fda.gov/MedicalDevices/DeviceRegulationandGuidance/GuidanceDocuments/default.htm
   Google Scholar
• CDRH innovation: CDRH device innovation initiative. www.fda.gov/AboutFDA/CentersOffices/OfficeofMedicalProductsandTobacco/CDRH/CDRHInnovation/default.htm
   Google Scholar
• Network of experts. www.fda.gov/AboutFDA/CentersOffices/OfficeofMedicalProductsandTobacco/CDRH/ucm289534.htm
   Google Scholar
• Premarket approval (PMA) simple search database. www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfPMA/pmasimplesearch.cfm
   Google Scholar
• Draft guidance for industry: coronary drug-eluting stents – nonclinical and clinical studies. www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/CM072193.pdf
   Google Scholar
• Draft guidance for industry and US FDA staff: the content of investigational device exemption (IDE) and premarket approval (PMA) applications for artificial pancreas device systems. www.fda.gov/MedicalDevices/DeviceRegulationandGuidance/GuidanceDocuments/ucm281706.htm
   Google Scholar
• Draft guidance for industry and US FDA staff: the content of investigational device exemption (IDE) and premarket approval (PMA) applications for low glucose suspend (LGS) device systems. www.fda.gov/MedicalDevices/DeviceRegulationandGuidance/GuidanceDocuments/ucm259301.htm
   Google Scholar
• Code of federal regulations title 21. Drugs for human use. www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfcfr/CFRsearch.cfm?CFRPart=314
   Google Scholar
• Transfer of therapeutic biological products to the CDER. www.fda.gov/CombinationProducts/JurisdictionalInformation/ucm136265.htm
   Google Scholar
• Examples of combination product approvals. www.fda.gov/CombinationProducts/AboutCombinationProducts/ucm101598.htm
   Google Scholar
• Medical device user fee and modernization action of 2002 (MDUFMA). www.fda.gov/MedicalDevices/DeviceRegulationandGuidance/Overview/MedicalDeviceUserFeeandModernizationActMDUFMA/ucm109133.htm
   Google Scholar
• Request for designation (RFD) process. www.fda.gov/CombinationProducts/RFDProcess/default.htm
   Google Scholar
• Jurisdictional update: drug-eluting cardiovascular stents. www.fda.gov/CombinationProducts/JurisdictionalInformation/JurisdictionalUpdates/ucm106552.htm
   Google Scholar
• US FDA. Combination products. www.fda.gov/CombinationProducts/default.htm
   Google Scholar
• Federal register. Volume 74, No. 183 (2009). www.gpo.gov/fdsys/pkg/FR-2009-09-23/pdf/E9-22850.pdf
   Google Scholar
• FDA regulatory information guidelines. www.fda.gov/RegulatoryInformation/Guidances
   Google Scholar